Nasdaq..7 Aug 2019 10:18
Was a no brainer, where a junior pharma needs to be as that's the market place for this kind of company. "Exposure", ? Well the fact that they raised nearly $80million for a company that was still early stage phase 2 would incline that they got some exposure. Following that the sp did rise and money was there for the making if you sold. Now as we all know, these funds were to be used for trials and that's exactly what's happened, the more positive these trials are, the better our chances are that this drug will make it to market, ie, funds reduced versus product derisked. The more the product is derisked, the better our chances of achieving a good price when more funds/partnering are needed as it enters phase 3. You can moan about the sp atm, but there are hundreds of companies in the same position as the markets take advantage a of the lul in sp action as we continue these trials. At what point these shares will trade at true value is controlled by results and financing events. Gla